Biohaven Pharmaceutical Holding Company Ltd

May 15, 2018

Biohaven Pharmaceuticals Reports First Quarter 2018 Financial and Recent Business Results

May 09, 2018

Biohaven Initiates Expanded Access Program for Sublingual BHV-0223 ZYDIS® Orally Dissolving Tablets for Patients with Amyotrophic Lateral Sclerosis (ALS)

Mar 12, 2018

Biohaven Restructures License Agreement With Bristol-Myers Squibb To Reduce Royalties Payable On Its Migraine Product Candidates; Transaction Financed Through Private Placement With Leading Institutional Investors

Nov 08, 2017

UPDATED : Portage announces its intention for its Biohaven shares

Nov 07, 2017

Portage announces its intention for its Biohaven shares